Institutional Repository UDD

The Antidiabetic Effect of MSCs is not Impaired by Insulin Prophylaxis and is not Improved by a Second Dose of Cells

Show simple item record

dc.contributor.author Ezquer, Fernando
dc.contributor.author Ezquer, Marcelo
dc.contributor.author Simon, Valeska
dc.contributor.author Conget, Paulette
dc.date.accessioned 2016-12-07T17:04:11Z
dc.date.available 2016-12-07T17:04:11Z
dc.date.issued 2011
dc.identifier.citation PLOS ONE, 2011, vol. 6, n° 1, Número de artículo: e16566
dc.identifier.uri http://hdl.handle.net/11447/874
dc.identifier.uri http://dx.doi.org/10.1371/journal.pone.0016566
dc.description.abstract Type 1 diabetes mellitus (T1D) is due to autoimmune destruction of pancreatic beta-cells. Previously, we have shown that intravenously administered bone marrow-derived multipotent mesenchymal stromal cells (MSCs) allows pancreatic islet recovery, improves insulin secretion and reverts hyperglycemia in low doses streptozotocin (STZ)-induced diabetic mice. Here we evaluate whether insulin prophylaxis and the administration of a second dose of cells affect the antidiabetic therapeutic effect of MSC transplantation. Insulitis and subsequent elimination of pancreatic beta-cells was promoted in C57BL/6 mice by the injection of 40 mg/kg/day STZ for five days. Twenty-four days later, diabetic mice were distributed into experimental groups according to if they received or not insulin and/or one or two doses of healthy donor-derived MSCs. Three and half months later: glycemia, pancreatic islets number, insulinemia, glycated hemoglobin level and glucose tolerance were determined in animals that did not received exogenous insulin for the last 1.5 months. Also, we characterized MSCs isolated from mice healthy or diabetic. The therapeutic effect of MSC transplantation was observed in diabetic mice that received or not insulin prophylaxis. Improvements were similar irrespective if they received one or two doses of cells. Compared to MSCs from healthy mice, MSCs from diabetic mice had the same proliferation and adipogenic potentials, but were less abundant, with altered immunophenotype and no osteogenic potential. Our preclinical results should be taken into account when designing phase II clinical trials aimed to evaluate MSC transplantation in patients with T1D. Cells should be isolated form healthy donor, insulin prophylaxis could be maintained and a second dose, after an elapse of two months, appears unnecessary in the medium-term.
dc.language.iso en_US
dc.subject Mesenchymal stem-cells
dc.subject Hepatocyte growth-factor
dc.subject Versus-host-disease
dc.subject Bone-marrow-cells
dc.subject Stromal cells
dc.subject Islet transplantation
dc.subject Progenitor cells
dc.subject Diabetic mice
dc.subject In-vitro
dc.subject Tissue-repair
dc.title The Antidiabetic Effect of MSCs is not Impaired by Insulin Prophylaxis and is not Improved by a Second Dose of Cells
dc.type Artículo


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account